Clinical Trial Update: GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating metronomic gemcitabine, doxorubicin, docetaxel, and nivolumab for advanced sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Gemzar (gemcitabine)
• OPDIVO (nivolumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Sarcoma Oncology Research Center, LLC | Conditions: Sarcoma | Phase 2 | Status: RECRUITING